An Open-Label Safety Extension Study (OLSES) Evaluating the Long Term Safety and Durability of Response of CHS-0214 (CHS-0214-05)

Trial Profile

An Open-Label Safety Extension Study (OLSES) Evaluating the Long Term Safety and Durability of Response of CHS-0214 (CHS-0214-05)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Plaque psoriasis; Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OLSES
  • Sponsors Coherus Biosciences
  • Most Recent Events

    • 04 Aug 2017 This trial has been completed in Germany.
    • 17 Jun 2017 Results of this and parent trial (see profile 244357) presented at the 18th Annual Congress of the European League Against Rheumatism
    • 05 Apr 2017 This trial has been completed in Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top